Pharma BD Deal Intelligence
Sumitovant Biopharma's $1.7B buyout of remaining Myovant Sciences shares consolidated full ownership of the specialty pharma, though the deal carried no disclosed upfront breakdown or named pipeline assets in the filing.
Sumitomo Pharma Sumitovant and Myovant enter definitive agreement for $27/share acquisition.
Sumitovant completes acquisition of Myovant Sciences for $27/share total transaction value $1.7 billion.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Sumitovant acquired remaining Myovant Sciences shares for $1.7B.
$4.5B US Uterine Fibroids Treatment Market (2024)
Myfembree (relugolix combination tablet) is an oral GnRH receptor antagonist approved for heavy menstrual bleeding from uterine fibroids (2021) and endometriosis-associated pain (2022). Uterine fibroids affect up to 80% of women by age 50, with ~26M US women affected. Endometriosis impacts ~11% of reproductive-age women. Relugolix offers an oral alternative to injectable GnRH agonists with rapid hormone suppression and recovery.
Myovant's portfolio centers on relugolix-based products: Myfembree for women's health (fibroids + endometriosis) and Orgovyx for advanced prostate cancer. Sumitovant (Sumitomo Pharma subsidiary) already owned 52% of Myovant and acquired remaining shares at $27/share after initially offering $22.75, which Myovant's board rejected.
Sumitovant completed $1.7B acquisition of remaining Myovant Sciences shares, gaining full ownership of Orgovyx and Myfembree.
Orgovyx continued growing in prostate cancer as oral GnRH antagonist, with Myfembree adding revenue in women's health.
Two growing commercial assets across oncology and women's health. $1.7B consolidated full ownership with clear commercial trajectory.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sumitovant Biopharma / Myovant Sciences Ltd. (this deal) | 2022 | $1.7B | 60 |
| Astellas Pharma Inc. / Ogeda SA | 2017 | $850M | 59 |
| Mylan Inc. / Famy Care Limited (women's healthcare businesses) | 2015 | $800M | 56 |
| Watson Pharmaceuticals (Actavis Inc.) / Uteron Pharma SA | 2013 | $305M | 16 |
| Organon & Co. / Forendo Pharma | 2021 | $954M | — |
| Sun Pharmaceutical Industries Ltd. / Organon & Co. | 2026 | $11.8B | — |
| Perrigo Company plc / HRA Pharma | 2021 | $2.1B | — |
← Browse all deals · How we score deals
More: 2022 deals · Women's Health deals